SS
LRMR icon

Steve Schonfeld’s Larimar Therapeutics LRMR Stock Holding History

Steve Schonfeld’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-38,090
Closed -$171K – 2827
2026
Q1 		$171K Sell
38,090
-23,669
-38% -$94.6K ﹤0.01% 1781
2025
Q4 		$235K Buy
+61,759
New +$240K ﹤0.01% 1649
2024
Q4 		– Sell
-242,476
Closed -$1.59M – 2231
2024
Q3 		$1.59M Buy
+242,476
New +$1.95M 0.01% 987
2024
Q2 		– Sell
-80,900
Closed -$614K – 2388
2024
Q1 		$614K Buy
+80,900
New +$630K ﹤0.01% 1407

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Steve Schonfeld's LRMR Position: Q2 2026 in Review

Steve Schonfeld sold out of Larimar Therapeutics (LRMR) in Q2 2026, closing a stake of 38,090 shares — an estimated $171K sold.

Steve Schonfeld first reported a position in LRMR in Q1 2024 and held it in 4 quarters. The position peaked at $1.59M in Q3 2024. 161 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Steve Schonfeld reported no remaining Larimar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Steve Schonfeld sold 38,090 Larimar Therapeutics shares in Q2 2026, an estimated $171K.
  • Steve Schonfeld first reported a position in Larimar Therapeutics in Q1 2024 and held it in 4 quarters.
  • Steve Schonfeld's Larimar Therapeutics position peaked at $1.59M in Q3 2024.
  • 161 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.